Clive Meanwell

Clive is Executive Chair and Founder of Population Health Partners, a global investment firm based in New York, San Francisco, and London, focused on technologies which arrest the drivers of common and burdensome health conditions such as stroke and heart disease, diabetes, lung diseases, chronic pain, anxiety and depression. He is also Vice Chairman of BB Biotech, the Swiss investor in biotechnology, and a board member of EQRx, a firm creating novel, patent-protected medicines at prices that are more affordable for people and sustainable for healthcare systems and of Comanche, a biotech start-up taking on the global problem of pre-eclampsia which is a leading cause of maternal death and premature births, particularly in low and middle income countries.

Clive was the founder, Chief Executive and Chief Innovation Officer of The Medicines Company, acquired by Novartis in early 2020 for $9.7 billion. Prior to that, he was a Partner at the venture capital firm MPM Capital, and before then, he held senior global executive positions with the Roche group working out of Switzerland and the United States. He trained in medicine, with post-graduate specialization in cancer treatment, cancer research, clinical trials, statistics, and epidemiology. He holds MB ChB and MD cum laude degrees from the University of Birmingham, UK.